Target Therapeutics buys Inverventional Therapeutics:
This article was originally published in Clinica
Target Therapeutics has completed the acquisition of fellow neuroradiology company Interventional Therapeutics through a stock swap. The two companies intend to integrate their operations and will offer a range of minimally invasive treatment options for vascular diseases of the brain. Target's product line includes microcatheters, guidewires and microcoils, while Interventional Therapeutics concentrates on vascular occlusion devices used in neurovascular embolisation, such as detachable silicone balloons.